Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
High level of vaccine efficacy maintained over a 6-month period of surveillance
Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)